"Cyclin E" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 50-kDa protein that complexes with CYCLIN-DEPENDENT KINASE 2 in the late G1 phase of the cell cycle.
| Descriptor ID |
D019927
|
| MeSH Number(s) |
D12.644.360.262.180 D12.776.167.218.180 D12.776.476.262.180
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cyclin E".
Below are MeSH descriptors whose meaning is more specific than "Cyclin E".
This graph shows the total number of publications written about "Cyclin E" by people in this website by year, and whether "Cyclin E" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1999 | 6 | 2 | 8 |
| 2000 | 5 | 1 | 6 |
| 2001 | 2 | 2 | 4 |
| 2002 | 1 | 3 | 4 |
| 2003 | 9 | 3 | 12 |
| 2004 | 5 | 4 | 9 |
| 2005 | 4 | 9 | 13 |
| 2006 | 5 | 0 | 5 |
| 2007 | 4 | 3 | 7 |
| 2008 | 3 | 3 | 6 |
| 2009 | 6 | 1 | 7 |
| 2010 | 7 | 3 | 10 |
| 2011 | 2 | 0 | 2 |
| 2012 | 2 | 3 | 5 |
| 2013 | 4 | 3 | 7 |
| 2014 | 1 | 2 | 3 |
| 2015 | 1 | 1 | 2 |
| 2016 | 3 | 1 | 4 |
| 2017 | 3 | 1 | 4 |
| 2018 | 2 | 1 | 3 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 0 | 2 |
| 2022 | 1 | 2 | 3 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclin E" by people in Profiles.
-
Low-Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer. Cancer Res. 2024 Nov 15; 84(22):3864-3880.
-
Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. Clin Cancer Res. 2023 11 01; 29(21):4385-4398.
-
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. J Clin Oncol. 2023 03 20; 41(9):1725-1734.
-
Low-molecular-weight cyclin E deregulates DNA replication and damage repair to promote genomic instability in breast cancer. Oncogene. 2022 Dec; 41(50):5331-5346.
-
Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences. Sci Rep. 2022 05 24; 12(1):8701.
-
CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models. Cell Rep Med. 2021 09 21; 2(9):100394.
-
Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer. Ann Surg. 2021 08 01; 274(2):e150-e159.
-
Two unique HLA-A*0201 restricted peptides derived from cyclin E as immunotherapeutic targets in leukemia. Leukemia. 2020 06; 34(6):1626-1636.
-
Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies. Cancer Res. 2018 10 01; 78(19):5481-5491.
-
Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition. Clin Cancer Res. 2018 12 15; 24(24):6594-6610.